A phase II clinical trial where MS patients were immunized with an altered peptide ligand based on an immunodominant MBP epitope, resulted in clinical exacerbations associated with an increase in the frequency of T cells specific for the MBP epitope in the CSF [79]. Here, MBP is linked to myeloid sarcoma.